Development of novel pretargeted PET radiopharmaceuticals for theranostics applications (TheraPET)
Bidragets beskrivning
Positron emission tomography (PET) is a diagnostic, non-invasive molecular imaging modality with great sensitivity. PET is an excellent diagnostic tool for personalized medicine for patient stratification prior to cancer treatments and for following individual response to the selected treatment. Recently, PET has emerged also as a promising diagnostic modality in theranostics. Theranostics combines both diagnostics and therapy, enabling disease monitoring, therapy and evaluation of treatment efficacy to enhance personalized and precision treatment strategies. PET has been investigated as a diagnostic companion in theranostics of cancer in combination with several treatment strategies such as with chemo-, radio- and immunotherapies and boron neutron capture therapy (BNCT). In the proposed project we will develop novel pretargeted theranostics for finding more efficient therapies to treat cancer.
Visa merStartår
2025
Slutår
2029
Beviljade finansiering
Finansiär
Finlands Akademi
Typ av finansiering
Akademiprojekt
Utlysning
Beslutfattare
Forskningsrådet för naturvetenskap och teknik
12.06.2025
12.06.2025
Övriga uppgifter
Finansieringsbeslutets nummer
371976
Vetenskapsområden
Kemi
Forskningsområden
Kemia